Novel therapeutics for the treatment of metastatic melanoma

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving 5 years after the diagnosis of less than 5%. To date, no systemic therapy has meaningfully changed these survival end points. Currently, in the USA the FDA has approved three agents for the treatment of metastatic melanoma: hydroxyurea, dacarbazine and interleukin-2. None of these have demonstrated a meaningfully prolonged survival of patients with metastatic melanoma. Therefore, a number of innovative therapeutic strategies have been pursued to improve outcomes, including immune therapy, tyrosine kinase inhibitors and angiogenesis inhibitors. Herein, we review some of the recent advances in novel therapeutic developments for the treatment of metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)543-557
Number of pages15
JournalFuture Oncology
Volume5
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Melanoma
Survival
Therapeutics
Dacarbazine
Angiogenesis Inhibitors
Hydroxyurea
Protein-Tyrosine Kinases
Interleukin-2

Keywords

  • Angiogenesis inhibitors
  • Immunotherapy
  • Metastatic melanoma
  • Novel therapeutics
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)
  • Oncology

Cite this

Novel therapeutics for the treatment of metastatic melanoma. / Mansfield, Aaron; Markovic, Svetomir Nenad.

In: Future Oncology, Vol. 5, No. 4, 2009, p. 543-557.

Research output: Contribution to journalArticle

@article{1226ef747a7846bdad33e6567a34928f,
title = "Novel therapeutics for the treatment of metastatic melanoma",
abstract = "Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving 5 years after the diagnosis of less than 5{\%}. To date, no systemic therapy has meaningfully changed these survival end points. Currently, in the USA the FDA has approved three agents for the treatment of metastatic melanoma: hydroxyurea, dacarbazine and interleukin-2. None of these have demonstrated a meaningfully prolonged survival of patients with metastatic melanoma. Therefore, a number of innovative therapeutic strategies have been pursued to improve outcomes, including immune therapy, tyrosine kinase inhibitors and angiogenesis inhibitors. Herein, we review some of the recent advances in novel therapeutic developments for the treatment of metastatic melanoma.",
keywords = "Angiogenesis inhibitors, Immunotherapy, Metastatic melanoma, Novel therapeutics, Tyrosine kinase inhibitors",
author = "Aaron Mansfield and Markovic, {Svetomir Nenad}",
year = "2009",
doi = "10.2217/fon.09.15",
language = "English (US)",
volume = "5",
pages = "543--557",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Novel therapeutics for the treatment of metastatic melanoma

AU - Mansfield, Aaron

AU - Markovic, Svetomir Nenad

PY - 2009

Y1 - 2009

N2 - Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving 5 years after the diagnosis of less than 5%. To date, no systemic therapy has meaningfully changed these survival end points. Currently, in the USA the FDA has approved three agents for the treatment of metastatic melanoma: hydroxyurea, dacarbazine and interleukin-2. None of these have demonstrated a meaningfully prolonged survival of patients with metastatic melanoma. Therefore, a number of innovative therapeutic strategies have been pursued to improve outcomes, including immune therapy, tyrosine kinase inhibitors and angiogenesis inhibitors. Herein, we review some of the recent advances in novel therapeutic developments for the treatment of metastatic melanoma.

AB - Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving 5 years after the diagnosis of less than 5%. To date, no systemic therapy has meaningfully changed these survival end points. Currently, in the USA the FDA has approved three agents for the treatment of metastatic melanoma: hydroxyurea, dacarbazine and interleukin-2. None of these have demonstrated a meaningfully prolonged survival of patients with metastatic melanoma. Therefore, a number of innovative therapeutic strategies have been pursued to improve outcomes, including immune therapy, tyrosine kinase inhibitors and angiogenesis inhibitors. Herein, we review some of the recent advances in novel therapeutic developments for the treatment of metastatic melanoma.

KW - Angiogenesis inhibitors

KW - Immunotherapy

KW - Metastatic melanoma

KW - Novel therapeutics

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=67651230913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651230913&partnerID=8YFLogxK

U2 - 10.2217/fon.09.15

DO - 10.2217/fon.09.15

M3 - Article

C2 - 19450181

AN - SCOPUS:67651230913

VL - 5

SP - 543

EP - 557

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -